Physician profile
Taylor A Womack
NPI 1316533748
$2,111.15
in general payments reported to CMS, 2019-2025
20 companies · $803 in 2025
The $803 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $75.06 · 2022: $330 · 2023: $653 · 2024: $250 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,705.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $405.62 | 2022-2025 | Qelbree, Qelbree |
| Astrazeneca Pharmaceuticals Lp | $319.23 | 2023-2025 | Airsupra, Tezspire, Fasenra |
| Abbvie INC. | $286.31 | 2023 | |
| Boston Scientific Corporation | $131.42 | 2023 | Watchman Access System |
| Amgen INC. | $122.57 | 2024-2025 | Otezla, Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $112.30 | 2021-2025 | Takhzyro |
| Glaxosmithkline, LLC. | $111.99 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Pharmacosmos Therapeutics INC. | $101.01 | 2023 | Monoferric |
| Regeneron Healthcare Solutions, INC. | $93.58 | 2025 | Dupixent |
| Csl Behring | $68.94 | 2025 | Andembry, Haegarda |
| Novartis Pharmaceuticals Corporation | $57.31 | 2025 | |
| Genzyme Corporation | $56.68 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $48.26 | 2025 | Neffy |
| Sanofi Pasteur INC. | $45.52 | 2022 | |
| Ionis Pharmaceuticals, INC. | $42.24 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $30.58 | 2022 | |
| Genentech USA, INC. | $25.65 | 2025 | Xolair |
| Seqirus USA INC | $19.05 | 2021 | |
| Cycle Pharmaceuticals INC | $18.82 | 2025 | Sajazir |
| Corium, LLC | $14.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Womack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.